- Details
- In this discussion, Phillip Koo welcomes Glen Gejerman to explore the integration of Lutetium-177 PSMA into large urology group practices. The conversation initially centers on the concept of an "authorized user," emphasizing its importance in radiation oncology and outlining the qualifications needed. Dr. Gejerman advises starting with a Radiation Safety Officer when identifying an authorized use...
|
- Details
- Phillip Koo engages with Gordon Brown and Glen Gejerman to explore the multidisciplinary aspects of integrating a Lutetium-177 PSMA program into a large urology practice. Dr. Brown outlines the meticulous patient identification and evaluation process, emphasizing the role of PSMA scans and FDA indications for Lu-177 therapy. Dr. Gejerman elaborates on the subsequent steps, including patient educat...
|
- Details
- Phillip Koo speaks with Thomas Hope about the published consensus statement on the use of lutetium-177-PSMA-617 radionuclide therapy for prostate cancer. The statement, published in the Journal of Nuclear Medicine, aims to guide clinicians on patient selection and appropriate use, particularly in complex cases. Dr. Hope emphasizes that the document goes beyond just outlining indications, diving in...
|
- Details
- Oliver Sartor discusses the rapidly evolving landscape of radiopharmaceuticals for prostate cancer with Alicia Morgans. Dr. Sartor highlights significant advances, such as the VISION trial, which targets late-stage patients and the PSMAfore trial focusing on pre-chemo patients. He emphasizes the importance of several ongoing trials that could change practice, including one using PSMA lutetium to t...
|
- Details
- In a discussion between Alicia Morgans and Karim Fizazi, they explore the quality of life outcomes from the VISION trial, published in Lancet Oncology. This Phase III trial examines the effects of Lutetium-PSMA-617 (also known as Pluvicto) on heavily pretreated metastatic castration-resistant prostate cancer patients. The study demonstrates a significant 38% reduction in the risk of death. Despite...
|
- Details
- Andrew Armstrong joins Andrea Miyahira in discussing a retrospective analysis of the prospective multicenter PROPHECY trial of men with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide seeking to develop a liquid biopsy using circulating tumor cells (CTCs) that they can associate with outcomes in men with mCRPC and ultimately apply that to a PSMA-tar...
|
- Details
- Renu Eapen, a recipient of the PCF Young Investigator Award, details her groundbreaking project on early use of Lutetium PSMA for high-risk localized prostate cancer. The two-cohort clinical trial involves administering Lutetium PSMA upfront, followed by radical prostatectomy. An integral part of the study is the translational work, analyzing changes in the tumor microenvironment in response to Lu...
|
- Details
- Phillip Kuo joins Alicia Morgans to discuss recent findings in a VISION sub-study. Dr. Kuo explains how this post-hoc exploratory analysis of the PSMA PET scans that were done for the VISION trial resulted in a better understanding of which patients are likely to respond better to treatment with lutetium-PSMA-617. Biographies: Phillip H. Kuo, MD, Ph.D., Professor of Medical Imaging, Medicine and B...
|
- Details
- Alicia Morgans has a conversation with Oliver Sartor regarding updates to the NCCN guidelines concerning patient selection for Lutetium treatment using PSMA PET scans. According to Dr. Sartor, the VISION trial based its approval of PSMA-617 Lutetium-177 on PSMA 11 gallium 68 in patient selection, but other PET scans are equally effective. The choice between PSMA-11 gallium-68 and DCFPYL F18 scans...
|
- Details
- Urologist Neal Shore joins Alicia Morgans in a discussion on the integration of lutetium into clinical practices. Dr. Shore reviews the phase 3 VISION trial which led to the approval of Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer. They discuss steps to thoughtfully and practically, integrate this new therapeutic into our treatment paradigm. Biographies: Neal Shore, MD...
|
